Trial Profile
A study evaluating the safety, tolerability, and pharmacokinetics of single and multiple oral doses of SUVN-502 in healthy young adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2018
Price :
$35
*
At a glance
- Drugs Masupirdine (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms FIH study
- 02 Feb 2018 New trial record
- 29 Jan 2018 Results published in the Clinical Drug Investigation